Abeona Therapeutics’ (ABEO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report published on Monday,Benzinga reports. HC Wainwright currently has a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.34) EPS, FY2024 earnings at ($1.16) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.17) EPS.

A number of other equities analysts have also recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 target price on shares of Abeona Therapeutics in a report on Tuesday, October 29th. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th.

Abeona Therapeutics Price Performance

NASDAQ:ABEO opened at $6.41 on Monday. The firm has a market capitalization of $278.64 million, a price-to-earnings ratio of -2.39 and a beta of 1.52. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The business has a 50 day simple moving average of $6.22 and a 200-day simple moving average of $5.32. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $9.01.

Hedge Funds Weigh In On Abeona Therapeutics

A number of large investors have recently bought and sold shares of the business. Geode Capital Management LLC boosted its holdings in Abeona Therapeutics by 21.7% during the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after acquiring an additional 83,050 shares during the period. XTX Topco Ltd purchased a new position in Abeona Therapeutics during the 3rd quarter valued at $160,000. Jane Street Group LLC purchased a new position in Abeona Therapeutics during the 3rd quarter valued at $84,000. Western Standard LLC boosted its holdings in Abeona Therapeutics by 7.0% during the 3rd quarter. Western Standard LLC now owns 1,698,097 shares of the biopharmaceutical company’s stock valued at $10,732,000 after acquiring an additional 110,998 shares during the period. Finally, Citigroup Inc. boosted its holdings in Abeona Therapeutics by 10.1% during the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after acquiring an additional 56,332 shares during the period. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.